Mark Merchant

10.4k total citations · 1 hit paper
64 papers, 4.9k citations indexed

About

Mark Merchant is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Merchant has authored 64 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 24 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Merchant's work include Melanoma and MAPK Pathways (14 papers), Liver physiology and pathology (12 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Mark Merchant is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), Liver physiology and pathology (12 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Mark Merchant collaborates with scholars based in United States, France and Canada. Mark Merchant's co-authors include Jeff Settleman, Richard Longnecker, Timothy R. Wilson, Hartmut Koeppen, Robert D. Dredge, Eric S. Lander, Yibing Yan, Emily Chan, John G. Moffat and Richard M. Neve and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Mark Merchant

62 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Timothy R. Wilson, Yibing Yan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Merchant United States	32	3.1k	1.6k	645	601	591	64	4.9k
Brad St. Croix United States	32	4.1k 1.3×	1.8k 1.1×	447 0.7×	444 0.7×	1.4k 2.4×	58	6.0k
Teresa L. Burgess United States	29	2.6k 0.8×	1.3k 0.8×	335 0.5×	259 0.4×	385 0.7×	44	4.1k
Masabumi Shibuya Japan	41	4.6k 1.5×	1.7k 1.0×	392 0.6×	455 0.8×	1.2k 2.0×	77	6.6k
Ana Rovira Spain	37	2.0k 0.6×	1.9k 1.2×	767 1.2×	284 0.5×	1.1k 1.9×	133	4.3k
Edward A. Fox United States	33	4.8k 1.6×	1.7k 1.0×	709 1.1×	1.8k 2.9×	1.2k 2.0×	53	7.4k
Michael Jeffers United States	36	3.4k 1.1×	1.6k 1.0×	770 1.2×	292 0.5×	997 1.7×	78	5.7k
Akihiro Kurimasa Japan	36	4.8k 1.6×	1.6k 1.0×	396 0.6×	468 0.8×	1.2k 2.0×	90	6.3k
Kevin M. Haigis United States	42	3.9k 1.3×	2.5k 1.6×	469 0.7×	496 0.8×	1.0k 1.7×	105	6.8k
Cristina Montagna United States	36	3.0k 1.0×	1.4k 0.8×	376 0.6×	811 1.3×	756 1.3×	124	4.8k
E. Aubrey Thompson United States	42	3.3k 1.1×	1.6k 1.0×	486 0.8×	404 0.7×	1.2k 2.0×	112	5.0k

Countries citing papers authored by Mark Merchant

Since Specialization

Citations

This map shows the geographic impact of Mark Merchant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Merchant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Merchant more than expected).

Fields of papers citing papers by Mark Merchant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Merchant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Merchant. The network helps show where Mark Merchant may publish in the future.

Co-authorship network of co-authors of Mark Merchant

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Merchant. A scholar is included among the top collaborators of Mark Merchant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Merchant. Mark Merchant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravichandran, Mirunalini, Jeff Lau, Jennifer A. Lacap, et al.. (2025). Data from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy. 1 indexed citations

Mutch, David G., Athina Voulgari, Xian Chen, et al.. (2024). Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer. Cancer. 130(11). 1940–1951. 2 indexed citations

Sodir, Nicole M., Gaurav Pathria, Joanne I. Adamkewicz, et al.. (2023). SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment. Cancer Discovery. 13(11). 2339–2355. 41 indexed citations

Zabka, Tanja S., Audrey Ruple, Dietrich Tuerck, et al.. (2021). Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma. Molecular Cancer Therapeutics. 20(11). 2177–2188. 18 indexed citations

Daemen, Anneleen, Matthew Wongchenko, Eva Lin, et al.. (2020). Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma. Clinical Cancer Research. 27(4). 1162–1173. 11 indexed citations

Sahu, Nisebita, Emily Chan, Felix Chu, et al.. (2017). Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(9). 1729–1738. 26 indexed citations

Jin, Lingyan, Emily Chan, Ehud Segal, et al.. (2017). Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research. 77(20). 5564–5575. 105 indexed citations

Yin, Yiyuan, Stevan Djakovic, Scot A. Marsters, et al.. (2015). Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Molecular Cancer Therapeutics. 14(10). 2270–2278. 6 indexed citations

Junttila, Melissa R., Vidusha Devasthali, Jason Chia‐Hsien Cheng, et al.. (2014). Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. Molecular Cancer Therapeutics. 14(1). 40–47. 43 indexed citations

10.

Raha, Debasish, Timothy R. Wilson, Jing Peng, et al.. (2014). The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Research. 74(13). 3579–3590. 223 indexed citations

11.

Penuel, Elicia, Congfen Li, Luciana Burton, et al.. (2013). HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 12(6). 1122–1130. 20 indexed citations

12.

Mai, Elaine, Zhong Zheng, Youjun Chen, et al.. (2013). Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab. Molecular Cancer Therapeutics. 13(2). 540–552. 10 indexed citations

13.

Lau, Ted, Emily Chan, Marinella Callow, et al.. (2013). A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. Cancer Research. 73(10). 3132–3144. 256 indexed citations

14.

Xiang, Hong, Brendan C. Bender, Arthur E. Reyes, et al.. (2013). Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development. Clinical Cancer Research. 19(18). 5068–5078. 28 indexed citations

15.

Lee, Ho‐June, Gabriele Schaefer, Timothy P. Heffron, et al.. (2012). Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M. Cancer Discovery. 3(2). 168–181. 68 indexed citations

16.

Du, Xiangnan, Emily Chan, Mark Merchant, et al.. (2012). FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth. Cancer Research. 72(22). 5843–5855. 72 indexed citations

17.

Hoeflich, Klaus P., Mark Merchant, Christine Orr, et al.. (2011). Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research. 72(1). 210–219. 200 indexed citations

18.

Jin, Harry, Renhui Yang, Zhong Zheng, et al.. (2008). MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival. Cancer Research. 68(11). 4360–4368. 171 indexed citations

19.

Merchant, Mark & Deepak Modi. (2004). Acute and chronic effects of aspirin on hematological parameters and hepatic ferritin expression in mice. Indian Journal of Pharmacology. 36(4). 226–230. 22 indexed citations

20.

Ikeda, Akiko, et al.. (2004). Latent Membrane Protein 2A, a Viral B Cell Receptor Homologue, Induces CD5+ B-1 Cell Development. The Journal of Immunology. 172(9). 5329–5337. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact